Chemomab Therapeutics

Company Overview

Snapshot

Founded in November 2011 by Adi Mor, Chemomab Therapeutics operates with 11–50 employees. The company has raised $90.5 million across 7 funding rounds from 12 investors. In March 2021, Chemomab Therapeutics completed a reverse merger with Anchiano Therapeutics and became publicly traded on NASDAQ.

Business overview

Chemomab Therapeutics is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's core technology centers on CM-101, a first-in-class monoclonal antibody designed to neutralize the activity of the soluble protein CCL24, which plays a pivotal role in promoting fibrosis and inflammation. Chemomab serves the healthcare and life sciences sectors, specifically targeting patients with severe and life-threatening conditions such as Primary Sclerosing Cholangitis (PSC) and NASH.

Strategic signal

In November 2023, Chemomab Therapeutics received FDA Fast Track Designation for CM-101 for the treatment of Primary Sclerosing Cholangitis. This designation indicates the FDA's recognition of CM-101's potential to address a serious condition with unmet medical needs, signaling a significant regulatory and clinical validation for the company's lead therapeutic candidate and potentially accelerating its development and review process.

Company Intelligence Q&A

What is Chemomab Therapeutics' primary therapeutic focus?

Chemomab Therapeutics is focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs, utilizing its CM-101 monoclonal antibody to neutralize CCL24 activity.

When did Chemomab Therapeutics become a public company?

Chemomab Therapeutics became public in March 2021, following a reverse merger with Anchiano Therapeutics, and is listed on NASDAQ.

What was a significant recent regulatory milestone for CM-101?

In November 2023, Chemomab Therapeutics received FDA Fast Track Designation for CM-101 for the treatment of Primary Sclerosing Cholangitis, highlighting its potential to address a serious condition.

What is the status of the global Phase 2 trial for CM-101 in Primary Sclerosing Cholangitis?

A global Phase 2 trial for CM-101 in Primary Sclerosing Cholangitis patients is ongoing, with top-line data readout targeted for the second half of 2024.

Who was appointed as Chief Executive Officer in September 2021?

In September 2021, Dale Pfost was appointed as the Chief Executive Officer of Chemomab Therapeutics.